Rockefeller Capital Management
MLYS icon

Rockefeller Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Rockefeller Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.58K Sell
244
-311
-56% -$8.53K ﹤0.01% 4167
2026
Q1 		$15K Buy
555
+421
+314% +$12.3K ﹤0.01% 3830
2025
Q4 		$4.86K Buy
134
+103
+332% +$4.13K ﹤0.01% 4079
2025
Q3 		$1.18K Buy
+31
New +$671 ﹤0.01% 4167

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rockefeller Capital Management's MLYS Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Mineralys Therapeutics (MLYS) stake by 56% in Q2 2026, selling an estimated $8.53K and leaving 244 shares worth $6.58K. The position accounts for ﹤0.01% of the portfolio, ranked #4167.

Rockefeller Capital Management first reported a position in MLYS in Q3 2025 and has held it in 4 quarters since. The position peaked at $15K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Rockefeller Capital Management held 244 shares of Mineralys Therapeutics worth $6.58K as of Q2 2026.
  • Rockefeller Capital Management sold 311 Mineralys Therapeutics shares in Q2 2026, an estimated $8.53K.
  • Mineralys Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4167 holding.
  • Rockefeller Capital Management first reported a position in Mineralys Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Mineralys Therapeutics position peaked at $15K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.